Skip to main content
logo
Apellis Pharmaceuticals, Inc. (APLS)
May 14, 2026 - APLS was delisted (reason: acquired by BIIB)
41.03
-0.03 (-0.07%)
Inactive · Last trade price on May 13, 2026

Apellis Pharmaceuticals Revenue by Segment

Period EndingDec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021
Product
689.38M690.21M689.03M696.78M709.95M657.44M580.05M490.56MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Product Growth
-2.90%4.99%18.79%42.04%93.83%165.87%249.90%434.47%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Collaboration License and Other
314.40M326.18M65.62M79.06M71.41M57.78M48.74M33.51MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Collaboration License and Other Growth
340.25%464.53%34.64%135.91%135.62%125.73%159.80%137.61%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade

Product Revenue by Segment

Period EndingDec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021
Syfovre
587.00M599.55M600.59M604.58M611.85M558.35M481.67M394.39MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Syfovre Growth
-4.06%7.38%24.69%53.30%122.26%246.84%462.03%2,048.08%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Empaveli
102.00M90.69M88.47M92.22M98.13M99.13M98.42M96.21MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Empaveli Growth
3.94%-8.52%-10.11%-4.15%7.79%14.81%22.81%30.91%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade